Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers. IMA101 is a personalized, multi-targeted investigational immunotherapy for the treatment of multiple advanced/ metastatic solid tumors.
by eazee-designstudio
Themis announced today that the US Food and Drug Administration (FDA) has granted fast track designation to the Company’s lead vaccine candidate (MV-CHIK) for the prevention of Chikungunya, a debilitating disease with global outbreak potential. The program is the most advanced Chikungunya vaccine candidate and has already successfully completed Phase 2 clinical development with results recently published in The Lancet.
AYOXXA today announced that it has signed a research agreement with one of the leading pharmaceutical companies. The agreement targets the development of low volume and high sensitivity multiplex assays for aqueous humor protein profiling for biomarker identification and validation in support of drug discovery in ophthalmology. The collaboration reflects an initial phase of a multi study plan in the field of ophthalmology and is a further step to establish AYOXXA LUNARISTM system as the standard for biomarker identification and validation in translational proteomics.
Adrenomed AG, the vascular integrity company, today announced the closing of a €24 million series D financing round. The new funds will be invested in the clinical development program of lead product candidate Adrecizumab. Adrecizunab is currently tested in a phase II clinical trial in patients with early septic shock and elevated plasma Adrenomedullin concentrations (bio-ADM).
The recently completed Phase 2 clinical trial was designed to assess the safety, tolerability and immunogenicity of its lead vaccine candidate (MV-CHIK) to protect against Chikungunya fever, a mosquito-transmitted disease that has no current treatment or prevention options. The primary endpoint, defined as the presence of neutralizing antibodies against Chikungunya, four weeks after administration of one or two MV-CHIK injections, was met across all treatment groups.
Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry.
German diagnostics company sphingotec GmbH has closed a €20m growth equity financing round led by international healthcare specialist investors HBM and Wellington Partners. Sphingotec will primarily use the proceeds to roll out the fully automated IB 10 point-of-care (POC) platform for testing of a broad panel of acute blood biomarkers, which had been acquired in May 2018 through an acquisition of Samsung-subsidiary Nexus Dx Inc.
Themis announced positive interim results from an ongoing phase 2 clinical study designed to demonstrate safety and immunogenicity of MV-CHIK, its live attenuated prophylactic vaccine candidate for chikungunya fever. The data will be presented for the first time at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in Baltimore, MA, USA.
Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately-held biotechnology company focused on the development of macrophage-based immunotherapeutics, today announced the close of a $53 million Series A financing to further expand its CAR-Macrophage platform – the first technology to combine antigen recognition with the effector function of macrophages – and to rapidly drive its programs toward clinical development.
TRiCares today announced the successful completion of a €22 million Series B financing round to fund the development of minimally invasive treatment of tricuspid regurgitation. Proceeds from the financing will be used to advance product development, to conduct clinical trials and to gain CE registration in Europe.
